6 completed, 6 recruiting, 2 active not recruiting, 2 terminated. 11 Phase 2, 7 Phase 1, 1 Not applicable, 1 Phase 3.
Follow Primary Mediastinal Large B-Cell Lymphoma: new trials by email Literature Review of Primary Mediastinal Large B-Cell Lymphoma trials Research Report on Primary Mediastinal Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Long-term Study to Evaluate Safety and Persistence of GF-CART01 DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL) | Enrolling by invitation | GenomeFrontier Therapeutics TW Co., Ltd. | 18 | 2026-02-26 | 2026-06-11 | |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment Non-Interventional Study - Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma | Recruiting | OHSU Knight Cancer Institute | 45 | 2025-03-10 | 2026-09-23 | |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
| Immunotherapy in Lymphoma CAR-T Therapy, Bispecific antibody, Antibody-Drug Conjugate - Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma | Recruiting | Sung-Soo Park | 72 | 2024-06-26 | 2025-01-28 | |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy Biopsy, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma | Phase 2 | Recruiting | Academic and Community Cancer Research United | 120 | 2024-01-31 | 2024-09-26 |
| Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Primary Mediastinal Large B-Cell Lymphoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 244 | 2021-10-05 | 2026-10-01 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | NeoImmuneTech | 17 | 2021-07-29 | 2026-08-10 |
| Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL) Circulating tumor DNA monitoring - Primary Mediastinal Large B-cell Lymphoma | Not applicable | Recruiting | Centre Henri Becquerel | 87 | 2021-03-22 | 2021-04-01 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 56 | 2020-10-27 | 2026-10-02 |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma | Phase 1 / Phase 2 | Terminated | Genmab | 46 | 2020-03-13 | 2024-10-24 |
| LITT and Pembrolizumab in Recurrent Brain Metastasis LITT + Pembrolizumab - Melanoma, Non-small Cell Lung Carcinoma (NSCLC) | Phase 1 | Terminated | University of Florida | 10 | 2020-01-10 | 2023-12-27 |
| Clinical Follow-up Study of CD19 CAR-T Expressing IL7 and CCL19 for Relapsed or Refractory B Cell Lymphoma CD19 CAR-T Expressing IL7 and CCL19 - Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | Completed | Second Affiliated Hospital, Zhejiang University, School of Medicine | 39 | 2018-09-22 | 2025-07-16 | |
| Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs Decitabine, GVD chemotherapy, SHR-1210 - Primary Mediastinal Large B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Chinese PLA General Hospital | 30 | 2017-05-01 | 2018-12-03 |
| Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) MDV9300 - Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | Medivation, Inc. | 2016-12-01 | 2016-11-25 | |
| Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma Ruxolitinib - Relapsed or Refractory Hodgkin Lymphoma, Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | Samsung Medical Center | 20 | 2013-11-15 | 2018-11-01 |
| Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL Tazemetostat, Prednisolone - B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1) | Phase 1 / Phase 2 | Completed | Epizyme, Inc. | 400 | 2013-06-13 | 2024-03-26 |
| CT-011 MAb in DLBCL Patients Following ASCT CT-011 - Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse | Phase 2 | Completed | CureTech Ltd | 72 | 2007-10-01 | 2014-09-12 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Etoposide, Rituximab, Prednisone - Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 348 | 1993-05-08 | 2025-06-22 |
Lymphoma, Large B-Cell, Diffuse (13) · Lymphoma, Follicular (5) · Recurrence (4) · Burkitt Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoma, Mantle-Cell (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Non-Hodgkin (2) · Brain Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Dendritic Cell Sarcoma, Interdigitating (1)
Neoplasms (17) · Neoplasms by Histologic Type (17) · Hemic and Lymphatic Diseases (16) · Immune System Diseases (16) · Immunoproliferative Disorders (16) · Lymphatic Diseases (16) · Lymphoma (16) · Lymphoproliferative Disorders (16) · Lymphoma, Non-Hodgkin (13) · Lymphoma, B-Cell (11) · Disease Attributes (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · DNA Virus Infections (4) · Infections (4)
Cyclophosphamide (6) · Doxorubicin (5) · Prednisone (5) · Rituximab (5) · Biopsy (4) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · deltacortene (4) · CT-P10 (3) · Etoposide (3) · prednylidene (3) · Antibodies, Monoclonal (2) · Methylprednisolone (2) · Prednisolone (2) · Vincristine (2)
National Cancer Institute (NCI) (2) · University of Washington (2) · Academic and Community Cancer Research United (1) · Centre Henri Becquerel (1) · Chinese PLA General Hospital (1) · CureTech Ltd (1) · Epizyme, Inc. (1) · Genmab (1) · GenomeFrontier Therapeutics TW Co., Ltd. (1) · Jonsson Comprehensive Cancer Center (1) · Marcela V. Maus, M.D.,Ph.D. (1) · Medivation, Inc. (1) · NeoImmuneTech (1) · OHSU Knight Cancer Institute (1) · Samsung Medical Center (1)
United States (14) · Australia (2) · Canada (2) · China (2) · France (2) · South Korea (2) · Taiwan (2) · Belgium (1) · Denmark (1) · Germany (1) · India (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1)
Amrita Desai (1) · Arnon Nagler, MD (1) · Grzegorz S Nowakowski (1) · John DiPersio, M.D. (1) · Leo I Gordon, MD (1) · Lisa G Roth (1) · Mark J Roschewski, M.D. (1) · Maryam Rahman, MD (1) · Matthew Frigault, MD (1) · Mengyang Di, MD, PhD (1) · Ryan Lynch (1) · Sven De Vos (1)
PMID 23574119, PMID 24127452, PMID 24224624, PMID 25024303, PMID 29650362, PMID 29748435, PMID 30125215, PMID 31707975, PMID 33035457, PMID 34432874, PMID 35882475, PMID 36521030, PMID 37981564, PMID 39563886, PMID 40802906
2019 (1), P30CA015083 (1), U10CA180886 (1)